Format

Send to

Choose Destination
Oncotarget. 2015 Aug 28;6(25):21755-60.

Dyskerin and TERC expression may condition survival in lung cancer patients.

Author information

1
Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, I-40138, Italy.
2
Department of Medical Oncology, S. Maria della Misericordia Hospital, Perugia, I-06156, Italy.
3
Department of Thoracic Surgery, University of Perugia, Perugia, I-06156, Italy.
4
Institute of Pathological Anatomy and Histology, University of Perugia, Perugia, I-06156, Italy.

Abstract

Dyskerin mediates both the modification of uridine on ribosomal and small nuclear RNAs and the stabilization of the telomerase RNA component (TERC). In human tumors dyskerin expression was found to be associated with both rRNA modification and TERC levels. Moreover, dyskerin overexpression has been linked to unfavorable prognosis in a variety of tumor types, however an explanation for the latter association is not available. To clarify this point, we analyzed the connection between dyskerin expression, TERC levels and clinical outcome in two series of primary lung cancers, differing for the presence of TERC gene amplification, a genetic alteration inducing strong TERC overexpression. TERC levels were significantly higher in tumors bearing TERC gene amplification (P = 0.017). In addition, the well-established association between dyskerin expression and TERC levels was observed only in the series without TERC gene amplification (P = 0.003), while it was not present in TERC amplified tumors (P = 0.929). Similarly, the association between dyskerin expression and survival was found in cases not bearing TERC gene amplification (P = 0.009) and was not observed in TERC amplified tumors (P = 0.584). These results indicate that the influence of dyskerin expression on tumor clinical outcome is linked to its role on the maintenance of high levels of TERC.

KEYWORDS:

TERC; TERC amplification; dyskerin; lung cancer; survival

PMID:
26301749
PMCID:
PMC4673301
DOI:
10.18632/oncotarget.4580
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center